Multi-ancestry investigation of the genomics of erectile dysfunction
Abstract
Erectile dysfunction is attributable to numerous biological and psychological issues, and its prevalence increases with age. We conducted genome-wide association studies of erectile dysfunction in AllofUs subjects of European and African ancestry, then meta-analyzed our findings with published datasets [NEuropean = 913,194 (136,867 cases); NAfrican = 125,315 (51,599 cases)]. We identified 40 independent variants in Europeans, two in Africans, and 51 cross-ancestry. In all analyses, the strongest effect variants mapped to a non-coding region known to regulate SIM1, previously associated with erectile dysfunction: rs78677597 (Europeans) (p = 5.32 × 10-139), and rs17185536 (Africans (p = 1.17 × 10-9) and cross-ancestry (p = 5.3 × 10-138)). Genetic correlations with psychiatric and health traits were moderate. Positive associations with phenotypes related to sexual drive may reflect ascertainment bias. This study is consistent with indications that erectile dysfunction is a complex trait influenced by multiple factors. Our findings emphasize the need to investigate genetic risk - SIM1 in particular further - to understand the mechanism through which they affect erectile function.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- 2024 update in heart failure
- Vascular involvement in idiopathic pulmonary fibrosis
- A novel technique- subendometrial autologous platelet rich plasma injection in patients with unresponsive thin endometrium undergoing frozen-thawed embryo transfer: a prospective cohort study
- Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial
- Combined Pulmonary Fibrosis and Emphysema (CPFE): A "New" Smoking-Related Interstitial Lung Disease (ILD)
- Impact of an acute 1-month cannabidiol treatment on pain and inflammation after a long bone fracture: a triple-blind randomised, placebo-controlled, clinical trial protocol
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.